Abstract
Atypical antipsychotic medications have largely supplanted their typical counterparts, both for psychosis and for the treatment of aggression and/or self-injurious behaviour (SIB), in persons with intellectual disabilities (ID). However, with the exception of risperidone, little systematic research supports their use in such persons. A retrospective review of 31 adult residents of a state developmental centre, who were treated for aggression and/or SIB with atypical antipsychotics. Average monthly counts of aggression and SIB for 1 year of treatment with typical antipsychotics, were compared with monthly averages for the next 12 months of treatment with atypical antipsychotics. Twenty-seven of 31 subjects (87%) completed a full year of atypical antipsychotic treatment. Subjects ranged in age from 24 to 54 years (mean = 39); 18/31 (58%) had profound ID. Twelve of 26 (46%) had typical antipsychotics discontinued within the year of atypical treatment; another 7/26 (27%) had their typical antipsychotic dose decreased. Twenty-three of 31 trials involved risperidone; 7/31 olanzapine; 1/31 quetiapine. Subjects gained an average of 6.6 pounds during the year of atypical treatment, but no significant changes in glucose or cholesterol we...Continue Reading
References
Nov 5, 1999·Journal of Intellectual Disability Research : JIDR·J Brylewski, L Duggan
Apr 6, 2000·Research in Developmental Disabilities·C D AdvokatJ L Matson
Jul 18, 2000·Journal of Intellectual Disability Research : JIDR·H WilliamsG Holt
Mar 15, 2001·The Journal of Clinical Psychiatry·S CohenA Khan
Oct 20, 2001·Journal of Child and Adolescent Psychopharmacology·J A HellingsS R Schroeder
Nov 6, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R FriedlanderJ Klancnik
Nov 16, 2001·American Journal of Mental Retardation : AJMR·J R ZarconeS R Schroeder
Feb 20, 2003·The Journal of Clinical Psychiatry·Seth CohenArif Khan
Nov 25, 2003·The Journal of Clinical Psychiatry·John A TsiourisWilliam M Korosh
Dec 9, 2003·The Journal of Clinical Psychiatry·David S JanowskyJohn M Davis
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Sep 18, 2004·Schizophrenia Research·Peter L ZhangGabriel A de Erausquin
Dec 8, 2004·Ethics & Behavior·Eric G Yan, Kerim M Munir
Jan 7, 2005·Journal of Intellectual Disability Research : JIDR·J RobertsonA Hallam
Jan 15, 2005·Journal of Child and Adolescent Psychopharmacology·Jennifer Cheng-ShannonJames T McCracken
Jan 27, 2005·The Journal of Clinical Psychiatry·Karen J ShedlackDaniel M Cheron
Jun 3, 2005·The American Journal of Psychiatry·Christopher J McDougleBenedetto Vitiello
Jun 10, 2005·Acta Psychiatrica Scandinavica. Supplementum·D NaberM Lambert
Jul 5, 2005·The American Journal of Psychiatry·UNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 29, 2005·The Journal of Clinical Psychiatry·Jerry R McKeeMelissa P Ball
Feb 2, 2006·Annals of Medicine·Dianna J MaglianoPaul Z Zimmet
Sep 7, 2007·Journal of Intellectual Disability Research : JIDR·L CharlotW McLlvane
Citations
Jan 29, 2011·Case Reports in Medicine·Michele FornaroSalvatore Colicchio
Apr 22, 2011·Journal of Intellectual Disability Research : JIDR·C PatonT Barnes
Jul 13, 2021·Frontiers in Psychiatry·Sophie LonchamptMarie Besson